{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T02:47:41Z","timestamp":1785034061695,"version":"3.55.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,12,2]],"date-time":"2020-12-02T00:00:00Z","timestamp":1606867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,12,2]],"date-time":"2020-12-02T00:00:00Z","timestamp":1606867200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Amsterdam UMC"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The added value of surgery in breast cancer patients with pathological complete response (pCR) after neoadjuvant systemic therapy (NST) is uncertain. The accuracy of imaging identifying pCR for omission of surgery, however, is insufficient. We investigated the accuracy of ultrasound-guided biopsies identifying breast pCR (ypT0) after NST in patients with radiological partial (rPR) or complete response (rCR) on MRI.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We performed a multicenter, prospective single-arm study in three Dutch hospitals. Patients with T1\u20134(N0 or N\u2009+) breast cancer with MRI rPR and enhancement\u2009\u2264\u20092.0\u00a0cm or MRI rCR after NST were enrolled. Eight ultrasound-guided 14-G core biopsies were obtained in the operating room before surgery close to the marker placed centrally in the tumor area at diagnosis (no attempt was made to remove the marker), and compared with the surgical specimen of the breast. Primary outcome was the false-negative rate (FNR).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Between April 2016 and June 2019, 202 patients fulfilled eligibility criteria. Pre-surgical biopsies were obtained in 167 patients, of whom 136 had rCR and 31 had rPR on MRI. Forty-three (26%) tumors were hormone receptor (HR)-positive\/HER2-negative, 64 (38%) were HER2-positive, and 60 (36%) were triple-negative. Eighty-nine patients had pCR (53%; 95% CI 45\u201361) and 78 had residual disease. Biopsies were false-negative in 29 (37%; 95% CI 27\u201349) of 78 patients. The multivariable associated with false-negative biopsies was rCR (FNR 47%; OR 9.81, 95% CI 1.72\u201355.89;<jats:italic>p\u2009<\/jats:italic>=\u20090.01); a trend was observed for HR-negative tumors (FNR 71% in HER2-positive and 55% in triple-negative tumors; OR 4.55, 95% CI 0.95\u201321.73;<jats:italic>p\u2009<\/jats:italic>=\u20090.058) and smaller pathological lesions (6\u00a0mm vs 15\u00a0mm; OR 0.93, 95% CI 0.87\u20131.00;<jats:italic>p\u2009<\/jats:italic>=\u20090.051).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The MICRA trial showed that ultrasound-guided core biopsies are not accurate enough to identify breast pCR in patients with good response on MRI after NST. Therefore, breast surgery cannot safely be omitted relying on the results of core biopsies in these patients.<\/jats:p><\/jats:sec>","DOI":"10.1245\/s10434-020-09273-0","type":"journal-article","created":{"date-parts":[[2020,12,2]],"date-time":"2020-12-02T16:08:26Z","timestamp":1606925306000},"page":"3243-3253","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":73,"title":["Minimally Invasive Complete Response Assessment of the Breast After Neoadjuvant Systemic Therapy for Early Breast Cancer (MICRA trial): Interim Analysis of a Multicenter Observational Cohort Study"],"prefix":"10.1245","volume":"28","author":[{"given":"Ariane A.","family":"van Loevezijn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marieke E.M.","family":"van der Noordaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik D.","family":"van Werkhoven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudette E.","family":"Loo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gonneke A. O.","family":"Winter-Warnars","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry","family":"Wiersma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koen K.","family":"van de Vijver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie J.","family":"Groen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte F. J. M.","family":"Blanken-Peeters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bas J.G.L.","family":"Zonneveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabe S.","family":"Sonke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederieke H.","family":"van Duijnhoven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Jeanne T. F. D.","family":"Vrancken Peeters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,12,2]]},"reference":[{"issue":"7","key":"9273_CR1","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S1470-2045(14)70160-3","volume":"15","author":"G von Minckwitz","year":"2014","unstructured":"von Minckwitz G, Schneeweiss A, Loibl S, et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol. 2014;15(7): 747\u2013756.","journal-title":"Lancet Oncol."},{"issue":"12","key":"9273_CR2","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/S1470-2045(18)30570-9","volume":"19","author":"MS van Ramshorst","year":"2018","unstructured":"van Ramshorst MS, van der Voort A, van Werkhoven ED, et al. Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2018;19(12): 1630\u20131640.","journal-title":"Lancet Oncol."},{"issue":"2","key":"9273_CR3","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.ejso.2018.09.027","volume":"45","author":"PER Spronk","year":"2019","unstructured":"Spronk PER, Volders JH, van den Tol P, Smorenburg CH, Vrancken Peeters M. Breast conserving therapy after neoadjuvant chemotherapy; data from the Dutch Breast Cancer Audit. Eur J Surg Oncol. 2019;45(2): 110\u2013117.","journal-title":"Eur J Surg Oncol."},{"key":"9273_CR4","doi-asserted-by":"crossref","unstructured":"Mieog JS, van der Hage JA, van de Velde CJ. Preoperative chemotherapy for women with operable breast cancer. Cochrane Database Syst Rev. 2007; (2): Cd005002.","DOI":"10.1002\/14651858.CD005002.pub2"},{"issue":"8","key":"9273_CR5","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1245\/s10434-013-2909-6","volume":"20","author":"HC Shin","year":"2013","unstructured":"Shin HC, Han W, Moon HG, et al. Breast-conserving surgery after tumor downstaging by neoadjuvant chemotherapy is oncologically safe for stage III breast cancer patients. Ann Surg Oncol. 2013; 20(8): 2582\u20132589.","journal-title":"Ann Surg Oncol."},{"issue":"3","key":"9273_CR6","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1245\/s10434-015-4918-0","volume":"23","author":"B Schaefgen","year":"2016","unstructured":"Schaefgen B, Mati M, Sinn HP, et al. Can Routine Imaging After Neoadjuvant Chemotherapy in Breast Cancer Predict Pathologic Complete Response? Ann Surg Oncol. 2016; 23(3): 789\u2013795.","journal-title":"Ann Surg Oncol."},{"issue":"8","key":"9273_CR7","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1634\/theoncologist.2015-0353","volume":"21","author":"S Sheikhbahaei","year":"2016","unstructured":"Sheikhbahaei S, Trahan TJ, Xiao J, et al. FDG-PET\/CT and MRI for Evaluation of Pathologic Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer: A Meta-Analysis of Diagnostic Accuracy Studies. Oncologist. 2016; 21(8): 931\u2013939.","journal-title":"Oncologist."},{"key":"9273_CR8","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1038\/bjc.2015.381","volume":"113","author":"J Heil","year":"2015","unstructured":"Heil J, K\u00fcmmel S, Schaefgen B, et al. Diagnosis of pathological complete response to neoadjuvant chemotherapy in breast cancer by minimal invasive biopsy techniques. Br J Cancer. 2015; 113: 1565.","journal-title":"Br J Cancer."},{"key":"9273_CR9","doi-asserted-by":"crossref","unstructured":"Francis A, Herring K, Molyneux R, et al. Abstract P5-16-14: NOSTRA PRELIM: A non randomised pilot study designed to assess the ability of image guided core biopsies to detect residual disease in patients with early breast cancer who have received neoadjuvant chemotherapy to inform the design of a planned trial. Cancer Res. 2017; 77(suppl 4): P5-16-14.","DOI":"10.1158\/1538-7445.SABCS16-P5-16-14"},{"key":"9273_CR10","doi-asserted-by":"crossref","unstructured":"Basik M, Costantino JP, Santos JFDL, et al. NRG Oncology BR005: Phase II trial assessing accuracy of tumor bed biopsies (Bx) in predicting pathologic response in patients (Pts) with clinical\/radiological complete response (CR) after neoadjuvant chemotherapy (NCT) in order to explore the feasibility of breast-conserving treatment (BCT) without surgery. J Clin Oncol. 2018; 36(suppl 15): TPS604-TPS04.","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS604"},{"issue":"suppl 15","key":"9273_CR11","first-page":"567-567","volume":"36","author":"MK Tasoulis","year":"2018","unstructured":"Tasoulis MK, Roche N, Rusby JE, et al. Post neoadjuvant chemotherapy vacuum assisted biopsy in breast cancer: Can it determine pathologic complete response before surgery? J Clin Oncol. 2018; 36(suppl 15): 567\u2013567.","journal-title":"J Clin Oncol."},{"issue":"7","key":"9273_CR12","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1245\/s10434-018-6481-y","volume":"25","author":"GM Rauch","year":"2018","unstructured":"Rauch GM, Kuerer HM, Adrada B, et al. Biopsy Feasibility Trial for Breast Cancer Pathologic Complete Response Detection after Neoadjuvant Chemotherapy: Imaging Assessment and Correlation Endpoints. Ann Surg Oncol. 2018; 25(7): 1953\u20131960.","journal-title":"Ann Surg Oncol."},{"issue":"5","key":"9273_CR13","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1097\/SLA.0000000000002313","volume":"267","author":"HM Kuerer","year":"2018","unstructured":"Kuerer HM, Rauch GM, Krishnamurthy S, et al. A clinical feasibility trial for identification of exceptional responders in whom breast cancer surgery can be eliminated following neoadjuvant systemic therapy. Ann Surg. 2018; 267(5): 946\u2013951.","journal-title":"Ann Surg."},{"key":"9273_CR14","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.ejca.2016.09.034","volume":"69","author":"J Heil","year":"2016","unstructured":"Heil J, Schaefgen B, Sinn P, et al. Can a pathological complete response of breast cancer after neoadjuvant chemotherapy be diagnosed by minimal invasive biopsy? Eur J Cancer. 2016; 69: 142\u2013150.","journal-title":"Eur J Cancer."},{"key":"9273_CR15","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.breast.2018.04.015","volume":"40","author":"MEM van der Noordaa","year":"2018","unstructured":"van der Noordaa MEM, van Duijnhoven FH, Loo CE, et al. Identifying pathologic complete response of the breast after neoadjuvant systemic therapy with ultrasound guided biopsy to eventually omit surgery: Study design and feasibility of the MICRA trial (Minimally Invasive Complete Response Assessment). Breast. 2018; 40: 76\u201381.","journal-title":"Breast."},{"key":"9273_CR16","doi-asserted-by":"crossref","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009; 45(2): 228\u2013247.","DOI":"10.1016\/j.ejca.2008.10.026"},{"issue":"4","key":"9273_CR17","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1111\/j.1365-2559.2006.02419.x","volume":"50","author":"SE Pinder","year":"2007","unstructured":"Pinder SE, Provenzano E, Earl H, Ellis IO. Laboratory handling and histology reporting of breast specimens from patients who have received neoadjuvant chemotherapy. Histopathology. 2007; 50(4): 409\u2013417.","journal-title":"Histopathology."},{"issue":"7","key":"9273_CR18","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1093\/annonc\/mdv161","volume":"26","author":"V Bossuyt","year":"2015","unstructured":"Bossuyt V, Provenzano E, Symmans WF, et al. Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration. Ann Oncol. 2015; 26(7): 1280\u20131291.","journal-title":"Ann Oncol."},{"issue":"5","key":"9273_CR19","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1093\/jnci\/djs528","volume":"105","author":"ML Marinovich","year":"2013","unstructured":"Marinovich ML, Houssami N, Macaskill P, et al. Meta-analysis of magnetic resonance imaging in detecting residual breast cancer after neoadjuvant therapy. J Natl Cancer Inst. 2013; 105(5): 321\u2013333.","journal-title":"J Natl Cancer Inst."},{"issue":"10","key":"9273_CR20","doi-asserted-by":"publisher","first-page":"2855","DOI":"10.1245\/s10434-017-5926-z","volume":"24","author":"HM Kuerer","year":"2017","unstructured":"Kuerer HM, Vrancken Peeters M, Rea DW, Basik M, De Los Santos J, Heil J. Nonoperative management for invasive breast cancer after neoadjuvant systemic therapy: conceptual basis and fundamental international feasibility clinical trials. Ann Surg Oncol. 2017; 24(10): 2855\u20132862.","journal-title":"Ann Surg Oncol."},{"issue":"suppl 15","key":"9273_CR21","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1200\/JCO.2018.36.15_suppl.566","volume":"36","author":"H-B Lee","year":"2018","unstructured":"Lee H-B, Kim S-Y, Kim KE, et al. Prediction of pathologic complete response by image-guided biopsy before surgery in breast cancer with complete clinical response to neoadjuvant chemotherapy: a prospective feasibility trial. J Clin Oncol. 2018; 36(suppl 15): 566.","journal-title":"J Clin Oncol."},{"key":"9273_CR22","doi-asserted-by":"crossref","unstructured":"Teoh V, Dumitru D, Tasoulis MK, MacNeill F. P088. Breast cancer patients with no surgery in the breast after an exceptional response to neoadjuvant chemotherapy: a case series. Eur J Surg Oncol. 2019; 45(5): 908.","DOI":"10.1016\/j.ejso.2019.01.110"},{"issue":"1","key":"9273_CR23","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1186\/s12885-018-4760-4","volume":"18","author":"J Heil","year":"2018","unstructured":"Heil J, Sinn P, Richter H, et al. RESPONDER\u2014diagnosis of pathological complete response by vacuum-assisted biopsy after neoadjuvant chemotherapy in breast Cancer\u2014a multicenter, confirmative, one-armed, intra-individually-controlled, open, diagnostic trial. BMC Cancer. 2018; 18(1): 851.","journal-title":"BMC Cancer."},{"key":"9273_CR24","doi-asserted-by":"crossref","unstructured":"Tasoulis MK, Lee H-B, Yang W, et al. Abstract GS5-04: Accuracy of post-neoadjuvant chemotherapy image-guided breast biopsy to predict the presence of residual cancer: A multi-institutional pooled analysis. Cancer Res. 2020; 80(4 Suppl):GS5-04-GS05-04.","DOI":"10.1158\/1538-7445.SABCS19-GS5-04"},{"key":"9273_CR25","doi-asserted-by":"crossref","unstructured":"Heil J, Pfob A, Sinn H-PP, et al. Abstract GS5-03: Diagnosing residual disease and pathologic complete response after neoadjuvant chemotherapy in breast cancer patients by image-guided vacuum-assisted breast biopsy: Results of a prospective multicenter trial. Cancer Res. 2020; 80(4 Suppl).GS5-03-GS05-03.","DOI":"10.1158\/1538-7445.SABCS19-GS5-03"},{"key":"9273_CR26","doi-asserted-by":"crossref","unstructured":"Basik M, Cecchini RS, Santos JFDL, et al. Abstract GS5-05: Primary analysis of NRG-BR005, a phase II trial assessing accuracy of tumor bed biopsies in predicting pathologic complete response (pCR) in patients with clinical\/radiological complete response after neoadjuvant chemotherapy (NCT) to explore the feasibility of breast-conserving treatment without surgery. Cancer Res. 2020; 80(4 Suppl):GS5-05-GS05-05.","DOI":"10.1158\/1538-7445.SABCS19-GS5-05"},{"issue":"9","key":"9273_CR27","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1177\/0284185114549224","volume":"56","author":"H Preibsch","year":"2015","unstructured":"Preibsch H, Baur A, Wietek BM, et al. Vacuum-assisted breast biopsy with 7-gauge, 8-gauge, 9-gauge, 10-gauge, and 11-gauge needles: how many specimens are necessary? Acta Radiol. 2015; 56(9): 1078\u20131084.","journal-title":"Acta Radiol."},{"issue":"1","key":"9273_CR28","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1148\/radiology.205.1.9314986","volume":"205","author":"WA Berg","year":"1997","unstructured":"Berg WA, Krebs TL, Campassi C, Magder LS, Sun CC. Evaluation of 14- and 11-gauge directional, vacuum-assisted biopsy probes and 14-gauge biopsy guns in a breast parenchymal model. Radiology. 1997; 205(1): 203\u2013208.","journal-title":"Radiology."},{"issue":"4","key":"9273_CR29","doi-asserted-by":"publisher","first-page":"238","DOI":"10.7326\/0003-4819-152-1-201001050-00190","volume":"152","author":"W Bruening","year":"2010","unstructured":"Bruening W, Fontanarosa J, Tipton K, Treadwell JR, Launders J, Schoelles K. Systematic review: comparative effectiveness of core-needle and open surgical biopsy to diagnose breast lesions. Ann Intern Med. 2010; 152(4): 238\u2013246.","journal-title":"Ann Intern Med."},{"issue":"15","key":"9273_CR30","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1200\/JCO.2011.38.8595","volume":"30","author":"G von Minckwitz","year":"2012","unstructured":"von Minckwitz G, Untch M, Blohmer JU, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012; 30(15): 1796\u20131804.","journal-title":"J Clin Oncol."},{"issue":"22","key":"9273_CR31","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","volume":"376","author":"N Masuda","year":"2017","unstructured":"Masuda N, Lee SJ, Ohtani S, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 2017; 376(22): 2147\u20132159.","journal-title":"N Engl J Med."},{"issue":"7","key":"9273_CR32","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa1814017","volume":"380","author":"G von Minckwitz","year":"2019","unstructured":"von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019; 380(7): 617\u2013628.","journal-title":"N Engl J Med."},{"issue":"7","key":"9273_CR33","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1001\/jamasurg.2017.0562","volume":"152","author":"AB Tadros","year":"2017","unstructured":"Tadros AB, Yang WT, Krishnamurthy S, et al. Identification of patients with documented pathologic complete response in the breast after neoadjuvant chemotherapy for omission of axillary surgery. JAMA Surg. 2017; 152(7):665\u2013670.","journal-title":"JAMA Surg."},{"issue":"6","key":"9273_CR34","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1245\/s10434-018-6404-y","volume":"25","author":"MEM van der Noordaa","year":"2018","unstructured":"van der Noordaa MEM, van Duijnhoven FH, Straver ME, et al. major reduction in axillary lymph node dissections after neoadjuvant systemic therapy for node-positive breast cancer by combining PET\/CT and the MARI procedure. Ann Surg Oncol. 2018; 25(6):1512\u20131520.","journal-title":"Ann Surg Oncol."},{"issue":"3","key":"9273_CR35","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s10549-020-05589-3","volume":"180","author":"JM Simons","year":"2020","unstructured":"Simons JM, Koppert LB, Luiten EJT, et al. De-escalation of axillary surgery in breast cancer patients treated in the neoadjuvant setting: a Dutch population-based study. Breast Cancer Res Treat. 2020; 180(3):725\u2013733.","journal-title":"Breast Cancer Res Treat."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-020-09273-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-020-09273-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-020-09273-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T00:53:37Z","timestamp":1669942417000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-020-09273-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,2]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["9273"],"URL":"https:\/\/doi.org\/10.1245\/s10434-020-09273-0","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,2]]},"assertion":[{"value":"29 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This work was supported by research grants from the Dutch Cancer Society (KWF, project NKI 2016-8210, Pink Ribbon 2016-206) and the Dutch Innovation Fund Health insurers (IFZ, project 3.642). GS received institutional research support from AstraZeneca, Merck, Novartis, and Roche. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}